We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews Drug Weekly
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews Device Weekly
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Resources
Form 483s Database
FDA Approved Drugs
White Papers
CenterWatch
About Us
The Company
FDAnews Editorial Board
Contact Us
Advertising
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Dawn C. Olenjack
Dawn C. Olenjack
Products
PRODUCTS
Danielle M.C. Brouquieres
Dawn C. Olenjack
Price:
$117.00
View
Mark R. Ryser
Stephen T. Hansen
,
Dawn C. Olenjack
, and
Theressa B. Smith
Price:
$117.00
View
Steven R. Lentz
Dawn C. Olenjack
Price:
$117.00
View
Chad M. Cannon
Dawn C. Olenjack
Price:
$117.00
View
Maria Wisniewska-Jarosinska
Dawn C. Olenjack
Price:
$117.00
View
Mel E. Lucas
Dawn C. Olenjack
Price:
$117.00
View
CoreLink, LLC
Dawn C. Olenjack
and
Eric M. Padgett
Price:
$117.00
View
Meridian Medical Technologies
Mary K. Concannon
,
Dawn C. Olenjack
, and
Michele Perry-Williams
Price:
$117.00
View
Upcoming Events
28
Sep
The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain
28
Sep
Calculating Sample Size to Satisfy FDA Expectations
11
Oct
GMP Quality Management vSummit 2023: Where Quality Meets Risk
16
Oct
MAGI@home Clinical Research Conference 2023
26
Oct
FDA in 2024: What to Expect in an Election Year
08
Nov
18th Annual FDA Inspections vSummit
Featured Products
FDA, FTC and DOJ Enforcement of Medical Device Regulations
Using Real-World Evidence in Drug and Device Submissions
Featured Stories
Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says
Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says
Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official
FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
